Loading
Life sciences · Journal article
Frontiers in Endocrinology · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Hypothyroidism and metabolic syndrome frequently coexist and share abnormalities in body weight, lipid metabolism, glucose regulation, and inflammatory signaling. Thyroid hormone deficiency can contribute to dyslipidemia, reduced energy expenditure, and impaired insulin action. By contrast, evidence that obesity, dyslipidemia, or insulin resistance directly causes thyroid dysfunction remains less established and is derived mainly from observational and experimental studies. This critical narrative review integrates current mechanistic and clinical evidence across obesity, dyslipidemia, and insulin resistance. It also examines implications for diagnosis, thyroid hormone replacement, metabolic treatment, monitoring, and future research. Clinical management should restore euthyroidism when thyroid treatment is indicated and address persistent obesity, dyslipidemia, and abnormal glucose metabolism according to their respective clinical indications. Longitudinal and interventional studies are needed to clarify causal direction and identify patient subgroups that may benefit from more individualized management.